CSL-backed biotech company Denteric has closed a $14 million funding round, enabling it to develop a vaccine for a gum disease that affects one in three adults globally, with a human clinical trial expected within three years.
The funding round was led by the Medical Research Commercialisation Fund’s Biomedical Translation Fund (BTF), managed by Brandon Capital Partners, with participation from CSL and the University of Melbourne.
Denteric is a newly formed spinout from the federal government’s Oral Health Co-operative Centre Program (CRC), based at the University of Melbourne.
Read the full article on the Australian Financial Review website.